Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in
participants with clinical symptoms of COVID-19 that have begun within the past 72 hours
prior to testing.